JP2020502224A - ヤヌスキナーゼ阻害剤の結晶形 - Google Patents

ヤヌスキナーゼ阻害剤の結晶形 Download PDF

Info

Publication number
JP2020502224A
JP2020502224A JP2019533666A JP2019533666A JP2020502224A JP 2020502224 A JP2020502224 A JP 2020502224A JP 2019533666 A JP2019533666 A JP 2019533666A JP 2019533666 A JP2019533666 A JP 2019533666A JP 2020502224 A JP2020502224 A JP 2020502224A
Authority
JP
Japan
Prior art keywords
crystals
crystalline form
crystal
composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019533666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502224A5 (OSRAM
Inventor
幸宏 神谷
幸宏 神谷
典昭 下山
典昭 下山
隆平 大倉
隆平 大倉
悟 野路
悟 野路
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of JP2020502224A publication Critical patent/JP2020502224A/ja
Publication of JP2020502224A5 publication Critical patent/JP2020502224A5/ja
Priority to JP2022207814A priority Critical patent/JP2023024729A/ja
Priority to JP2024134769A priority patent/JP2024161449A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019533666A 2016-12-21 2017-12-20 ヤヌスキナーゼ阻害剤の結晶形 Pending JP2020502224A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022207814A JP2023024729A (ja) 2016-12-21 2022-12-26 ヤヌスキナーゼ阻害剤の結晶形
JP2024134769A JP2024161449A (ja) 2016-12-21 2024-08-13 ヤヌスキナーゼ阻害剤の結晶形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437262P 2016-12-21 2016-12-21
US62/437,262 2016-12-21
PCT/JP2017/045731 WO2018117153A1 (en) 2016-12-21 2017-12-20 Crystalline forms of a janus kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022207814A Division JP2023024729A (ja) 2016-12-21 2022-12-26 ヤヌスキナーゼ阻害剤の結晶形

Publications (2)

Publication Number Publication Date
JP2020502224A true JP2020502224A (ja) 2020-01-23
JP2020502224A5 JP2020502224A5 (OSRAM) 2021-02-04

Family

ID=60991475

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019533666A Pending JP2020502224A (ja) 2016-12-21 2017-12-20 ヤヌスキナーゼ阻害剤の結晶形
JP2022207814A Pending JP2023024729A (ja) 2016-12-21 2022-12-26 ヤヌスキナーゼ阻害剤の結晶形
JP2024134769A Pending JP2024161449A (ja) 2016-12-21 2024-08-13 ヤヌスキナーゼ阻害剤の結晶形

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022207814A Pending JP2023024729A (ja) 2016-12-21 2022-12-26 ヤヌスキナーゼ阻害剤の結晶形
JP2024134769A Pending JP2024161449A (ja) 2016-12-21 2024-08-13 ヤヌスキナーゼ阻害剤の結晶形

Country Status (13)

Country Link
US (1) US11339181B2 (OSRAM)
EP (1) EP3559003B1 (OSRAM)
JP (3) JP2020502224A (OSRAM)
KR (1) KR102788829B1 (OSRAM)
CN (2) CN121045220A (OSRAM)
AU (1) AU2017380213B2 (OSRAM)
BR (1) BR112019012210A2 (OSRAM)
CA (1) CA3044771A1 (OSRAM)
ES (1) ES2926986T3 (OSRAM)
IL (1) IL267393B2 (OSRAM)
MX (1) MX386181B (OSRAM)
TW (1) TWI822666B (OSRAM)
WO (1) WO2018117153A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024527105A (ja) * 2021-07-30 2024-07-19 イーライ リリー アンド カンパニー バリシチニブによる手湿疹の治療

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3047891A1 (en) 2016-12-21 2018-06-28 Japan Tobacco Inc. Process for preparing 7h-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof
CN118903144A (zh) * 2019-08-07 2024-11-08 乐敦制药株式会社 泪液分泌促进用眼科组合物
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
WO2024180493A1 (en) 2023-02-28 2024-09-06 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
WO2024225445A1 (en) * 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011046700A (ja) * 2009-07-31 2011-03-10 Japan Tobacco Inc 含窒素スピロ環化合物及びその医薬用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090296332A1 (en) * 2005-07-07 2009-12-03 Thomson Licensing Flat-Screen Display System With Corresponding Sleeves
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
PL2432472T3 (pl) * 2009-05-22 2020-03-31 Incyte Holdings Corporation 3-[4-(7H-Pirolo[2,3-d]pirymidyn-4-ylo)-1H-pirazol-1-ilo]oktano- lub heptano-nitryle jako inhibitory JAK
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
US20160367556A1 (en) * 2013-10-21 2016-12-22 Japan Tobacco Inc. Therapeutic Agent for Ocular Disease or Prophylactic Agent for Ocular Disease
HK1251223A1 (en) * 2015-07-07 2019-01-25 Japan Tobacco, Inc. Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011046700A (ja) * 2009-07-31 2011-03-10 Japan Tobacco Inc 含窒素スピロ環化合物及びその医薬用途

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
PHARM STAGE, vol. 6, JPN6011001457, 2007, pages 48 - 53, ISSN: 0004881475 *
実験化学講座（続）２ 分離と精製, JPN6012022299, 25 January 1967 (1967-01-25), pages 159 - 178, ISSN: 0004881479 *
新・薬剤学総論（改訂第３版）, vol. 株式会社南江堂, JPN6012025458, 10 April 1987 (1987-04-10), pages 111, ISSN: 0004881474 *
新製剤学, JPN6012022297, 25 April 1984 (1984-04-25), pages 102 - 103, ISSN: 0004881473 *
有機合成化学協会誌, vol. 65, JPN6010003277, 2007, pages 907 - 913, ISSN: 0004881477 *
第十六改正 日本薬局方, JPN6014035187, 2011, pages 64 - 68, ISSN: 0004881471 *
芦澤一英 他, 医薬品の多形現象と晶析の科学, JPN6018037400, 20 September 2002 (2002-09-20), JP, pages 3 - 16, ISSN: 0004881478 *
調剤学−基礎と応用−, JPN6012022295, 20 September 1977 (1977-09-20), pages 142 - 145, ISSN: 0004881472 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0004881476 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024527105A (ja) * 2021-07-30 2024-07-19 イーライ リリー アンド カンパニー バリシチニブによる手湿疹の治療

Also Published As

Publication number Publication date
US11339181B2 (en) 2022-05-24
TW201829423A (zh) 2018-08-16
CN110325536A (zh) 2019-10-11
IL267393A (en) 2019-08-29
JP2024161449A (ja) 2024-11-19
BR112019012210A2 (pt) 2019-11-12
WO2018117153A1 (en) 2018-06-28
EP3559003B1 (en) 2022-08-24
JP2023024729A (ja) 2023-02-16
CA3044771A1 (en) 2018-06-28
KR20190092440A (ko) 2019-08-07
RU2019122566A3 (OSRAM) 2021-12-22
IL267393B2 (en) 2023-07-01
MX386181B (es) 2025-03-18
KR102788829B1 (ko) 2025-03-31
RU2019122566A (ru) 2021-01-22
TWI822666B (zh) 2023-11-21
EP3559003A1 (en) 2019-10-30
ES2926986T3 (es) 2022-10-31
AU2017380213B2 (en) 2022-01-06
MX2019007462A (es) 2019-08-29
IL267393B1 (en) 2023-03-01
US20200017527A1 (en) 2020-01-16
AU2017380213A1 (en) 2019-05-23
CN121045220A (zh) 2025-12-02

Similar Documents

Publication Publication Date Title
JP2024161449A (ja) ヤヌスキナーゼ阻害剤の結晶形
US10723730B2 (en) Solid forms of a selective CDK4/6 inhibitor
BR122021004509B1 (pt) Sais de inibidor de pi3k e processos para seu preparo
EP4332102A1 (en) Isoquinolone compound and use thereof
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
US12435036B2 (en) Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-n,n-dimethylpropan-2-amine
KR20210114470A (ko) 결정질 피리미디닐-3,8-다이아자바이사이클로[3.2.1]옥타닐메타논 화합물 및 이의 용도
US11230559B2 (en) Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate
TW201736352A (zh) 經取代之５，６－二氫－６－苯基苯并［ｆ］異喹啉－２－胺化合物之固體形式
TW202334120A (zh) 經取代之哌啶化合物之結晶以及經取代之哌啶化合物之鹽及其等之結晶
EP2975035B1 (en) Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof
RU2838992C2 (ru) Кристаллические формы ингибитора янус-киназы
CN112543634A (zh) Ebna1抑制剂晶体形式及其制备和使用方法
US20230399331A1 (en) Solid forms of jak inhibitor and process of preparing the same
US20250333381A1 (en) Solid state forms
BR122024025362A2 (pt) Formas cristalinas de um inibidor de janus cinase, composição farmacêutica compreendendo as ditas formas cristalinas, seu uso e métodos de medição
US10822336B2 (en) Crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and pharmaceutically acceptable salt thereof
HK40050819A (en) Ebna1 inhibitor crystalline forms, and methods of preparing and using same
EA046959B1 (ru) Фармацевтическая композиция для перорального введения, содержащая производное аминопиримидина или его соль

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220927